The Pulse of Medical Art,
Attaining Unity to Achieve Rectitude.
{{getlocset2('name1')}}
认识脉得
ABOUT
MED
脉得智能是一家行业前沿的人工智能医疗科技企业
，专注人工智能医学大数据算法研究领域，由院士团队与国内杰出运营团队联合成立。公司以强大的人工智能原研团队为支撑，联合国内权威三甲医院专家医疗团队，实现基于超声影像的多病种AI实时专家诊疗系统和基于基因组学的Al生信数据分析平台。
公司目前是国家高新技术企业，江苏省潜在独角兽企业，江苏省专精特新企业，“全国精准医学产业创新中心”常务理事单位，江苏省人工智能学会理事单位，获得了省市及国家各级的多项人才荣誉和重点项目奖励。
公司分别在中国无锡、上海和成都设立总部、区域总部、研发中心和重点联合实验室。同时，作为细分赛道行业标杆品牌与全球头部战略级合作伙伴达成深度战略合作，业务覆盖数百家头部知名医疗机构及基层医疗机构，共同推动精准医疗整体解决方案的商业化运营。
公司产品平台也先后获得了全国创新创业大赛全国总决赛优秀企业项目，江苏省人工智能科学技术奖，江苏省优秀人工智能产品等荣誉，并获评工信部全国人工智能医疗器械创新任务揭榜挂帅优胜单位，2023年在创客中国江苏省创新创业大赛中也已经入围百强项目等。
MED Imaging AI is an innovative technology enterprise focusing on artificial
intelligence algorithm research, service integration, and AI technical services. Founded
by an academician team, the company boasts strong comprehensive research capabilities in
artificial intelligence at its overseas laboratories. It focuses on exploring the
innovative path of precision medicine based on AI-assisted disease diagnosis and
treatment via medical imaging, as well as AI-driven bioinformatics analysis and
interpretation based on genetic testing. Through innovations in medical data cognition
and professional medical imaging processing and analysis systems, the company has built
a complete overall solution for precision medicine.
AI Clinical Application Scenarios and genomics-related areas covering healthy
populations, susceptibility genes, and pathogenic microorganisms. MED Imaging AI's
overall precision medicine solution has been implemented and cooperated with a large
number of top domestic medical institutions to jointly promote commercial operations,
making it the leading brand with unparalleled brand strength and coverage in the
vertical clinical field nationwide.
发展历程
MED HISTORY
.png)
备份.png)
2025
•
联合华为、广东省第二人民医院等机构发布数智超声大模型
•
获得全球首张对标病理的三类证获得上海市科技进步一等奖
•
获得国家“四大慢病”重大专项
•
“高质量多模态医疗数据集”项目入选国家数据局行业高质量数据集建设试点
•
落地覆盖医院：超500+家医院，辐射机构上千家
•
正式拓展海外市场
•
多个临床数据基地成立
•
Jointly launched the digital intelligent ultrasound large model with
Huawei, the Second People's Hospital of Guangdong Province and other
institutions
•
Obtained the world's first Class III Medical Device Registration
Certificate aligned with pathological standards
•
Awarded the First Prize of Shanghai Science and Technology Progress
Award
•
Secured the national major special project for "Four Major Chronic
Diseases"
•
The "High-Quality Multimodal Medical Dataset" project was selected for
the National Data Administration's industry high-quality dataset
construction pilot
•
Deployment coverage: Over 500 hospitals, reaching over a thousand
institutions
•
Officially expanded into overseas markets
•
Multiple clinical data bases established
2024-2023
新品上市
•
IBS： 完成多中心实验
•
IAS： 覆盖多脏器超声AI诊断
•
声奈特： 超声智能远程质控整体解决方案
•
大数据平台： 高质量金标准医疗数据整理、清洗及分析
•
生物信息系统平台产品 验证落地
国家级项目合作
•
《千县工程》
县域超声能力建设综合项目合作伙伴，推动县域超声能力提升
•
国家工信部揭榜挂帅多项重点项目
•
申报国家科技重点奖项
•
Launched IBS: The pathological gold-standard AI-assisted diagnosis
product for breast ultrasound
•
Launched ILS: the pathological gold-standard AI-assisted diagnosis
product for lymph node ultrasound
•
Launched IAS: the multi-organ integrated ultrasound AI diagnosis product
•
Bioinformatics system platform product approved and launched
•
CityU-MedAITech Joint Lab established
•
Became a strategic partner of the "Thousand-County Project", covering
over 200 hospitals
•
Recognized as a winning organization in the “AI Medical Device
Innovation Task Leaderboard Program” organized by the Ministry of
Industry and Information Technology and the National Medical Products
Administration.
•
Recognized as a Potential Unicorn Enterprise and a "Specialized,
Sophisticated, Distinctive, and Novel" Enterprise in Jiangsu Province
2022
•
成功入选工信部人工智能医疗器械创新任务揭榜挂帅入围-优胜单位；
获得江苏省人工智能科学技术奖；江苏省优秀人工智能产品
•
入选“滨湖之光”、“太湖人才”、省双创
等国家及省市级人才计划
•
获得了多张浅表脏器超声领域的二类医疗器械注册证；甲状腺超声三类证进入尾声
•
完成C轮融资
•
扩大科研与商业覆盖，达成数十项临床多中心重点合作以及省市级重点项目；
•
拓展商业覆盖，覆盖200多家医院
•
Selected by the Ministry of Industry and Information Technology as a
lead unit for the AI medical-device innovation challenge
•
Awarded the Jiangsu Provincial Artificial Intelligence Science and
Technology Award
•
Obtained multiple Class II medical device registration certificates in
the field of superficial organ ultrasound; nearing completion of the
Class III certification for thyroid ultrasound
•
Completed Series C financing
•
Secured dozens of key clinical multi-center collaborations as well as
provincial and municipal-level key projects
•
Expanded commercial coverage to over 200 hospitals
2021
•
省市两级准独角兽，入选 “滨湖之光”、“太湖人才” 等计划
•
完成A及B轮融资
•
ITS 获得二类证，三类证，临床试验多中心启动
•
成功亮相全国会议，开始商业化运营，在TOP100医院布局
•
Series A Financing
•
Series B Financing
•
Recognized as a National High-Tech Enterprise and a Potential Unicorn
Enterprise in Wuxi
•
Launched the IBS series of AI products for breast ultrasound
•
Launched and carried out genomics-bioinformatics business
•
Selected for national, provincial and municipal talent programs national
and provincial/municipal talent programs such as “Light of Binhu”,
“Taihu Talent”, the Provincial Dual-Innovation Program, and the Qiming
Talent Program.
•
Obtained NMPA registration and launched commercial operations; completed
the layout in China's TOP 100 hospitals
2020
•
完成 高企、瞪羚 资质入库
•
ITS100在知名合作医院试用落地
•
启动 NMPA注册证二类、三类证申报
•
陆续达成与上市公司的重要渠道战略合作
•
拓展基于超声AI多种疾病产品研发
•
Completed the recognition of "High and new technology enterprises to
cultivate storage"
•
Recognized as a Gazelle Enterprise in Wuxi
•
Launched the ITS series of AI products for thyroid ultrasound and
initiated NMPA registration
•
Western Data Center established; initiated the high-quality gold
standard data construction project
•
Expanded research and development of ultrasound AI products for multiple
diseases
2019
•
完成天使轮融资
•
核心创始团队回国落地
•
落户无锡
•
成都研发中心落地
•
与全国多家医院联合，多病种方向进行科研合作
•
选定超声人工智能作为公司战略方向
•
完成ITS100多中心方案设计
•
ITS系列产品1.0版本研发成功
•
Completed angel round financing
•
Core founding team returned to China and established operations
•
Settled in Wuxi
•
Chengdu R&D center established
•
Conducted scientific research collaborations with multiple hospitals
nationwide across various disease areas
•
Selected ultrasound artificial intelligence as the company's strategic
direction
•
Completed the multi-center protocol design for ITS100
•
ITS series products version 1.0 successfully developed
2025
2024-2023
2022
2021
2020
2019
{{getlocset2('name2')}}
{{getlocset2('name3')}}
{{getlocset2('name4')}}
{{getlocset2('name5')}}
{{getlocset2('name6')}}
{{getlocset2('name7')}}
{{getlocset2('name8')}}
{{getlocset2('name9')}}
{{getlocset2('name10')}}
.svg)
{{getlocset('about')}}
{{getlocset('Produc')}}
脉得智能是一家行业前沿的人工智能医疗科技企业
，专注人工智能医学大数据算法研究领域，由院士团队与国内杰出运营团队联合成立。公司以强大的人工智能原研团队为支撑，联合国内权威三甲医院专家医疗团队，实现基于超声影像的多病种AI实时专家诊疗系统和基于基因组学的Al生信数据分析平台。
公司目前是国家高新技术企业，江苏省潜在独角兽企业，江苏省专精特新企业，“全国精准医学产业创新中心”常务理事单位，江苏省人工智能学会理事单位，获得了省市及国家各级的多项人才荣誉和重点项目奖励。
公司分别在中国无锡、上海和成都设立总部、区域总部、研发中心和重点联合实验室。同时，作为细分赛道行业标杆品牌与全球头部战略级合作伙伴达成深度战略合作，业务覆盖数百家头部知名医疗机构及基层医疗机构，共同推动精准医疗整体解决方案的商业化运营。
公司产品平台也先后获得了全国创新创业大赛全国总决赛优秀企业项目，江苏省人工智能科学技术奖，江苏省优秀人工智能产品等荣誉，并获评工信部全国人工智能医疗器械创新任务揭榜挂帅优胜单位，2023年在创客中国江苏省创新创业大赛中也已经入围百强项目等。
MED Imaging AI is an innovative technology enterprise focusing on artificial
intelligence algorithm research, service integration, and AI technical services. Founded
by an academician team, the company boasts strong comprehensive research capabilities in
artificial intelligence at its overseas laboratories. It focuses on exploring the
innovative path of precision medicine based on AI-assisted disease diagnosis and
treatment via medical imaging, as well as AI-driven bioinformatics analysis and
interpretation based on genetic testing. Through innovations in medical data cognition
and professional medical imaging processing and analysis systems, the company has built
a complete overall solution for precision medicine.
AI Clinical Application Scenarios and genomics-related areas covering healthy
populations, susceptibility genes, and pathogenic microorganisms. MED Imaging AI's
overall precision medicine solution has been implemented and cooperated with a large
number of top domestic medical institutions to jointly promote commercial operations,
making it the leading brand with unparalleled brand strength and coverage in the
vertical clinical field nationwide.
发展历程
MED
HISTORY
HISTORY
{{yename}}
2025
2024
—
2023
—
2023
2022
2021
2020
2019
•
联合华为、广东省第二人民医院等机构发布数智超声大模型
•
获得全球首张对标病理的三类证获得上海市科技进步一等奖
•
获得国家“四大慢病”重大专项
•
“高质量多模态医疗数据集”项目入选国家数据局行业高质量数据集建设试点
•
落地覆盖医院：超500+家医院，辐射机构上千家
•
正式拓展海外市场
•
多个临床数据基地成立
•
Jointly launched the digital
intelligent ultrasound large model with
Huawei, the Second People's Hospital of Guangdong Province and other
institutions
•
Obtained the world's first
Class III Medical Device Registration
Certificate aligned with pathological standards
•
Awarded the First Prize of
Shanghai Science and Technology Progress
Award
•
Secured the national major
special project for "Four Major Chronic
Diseases"
•
The "High-Quality Multimodal
Medical Dataset" project was selected for
the National Data Administration's industry high-quality dataset
construction pilot
•
Deployment coverage: Over 500
hospitals, reaching over a thousand
institutions
•
Officially expanded into
overseas markets
•
Multiple clinical data bases
established
新品上市
•
IBS： 完成多中心实验
•
IAS： 覆盖多脏器超声AI诊断
•
声奈特： 超声智能远程质控整体解决方案
•
大数据平台： 高质量金标准医疗数据整理、清洗及分析
•
生物信息系统平台产品 验证落地
国家级项目合作
•
《千县工程》
县域超声能力建设综合项目合作伙伴，推动县域超声能力提升
•
国家工信部揭榜挂帅多项重点项目
•
申报国家科技重点奖项
•
Launched IBS: The pathological
gold-standard AI-assisted diagnosis
product for breast ultrasound
•
Launched ILS: the pathological
gold-standard AI-assisted diagnosis
product for lymph node ultrasound
•
Launched IAS: the multi-organ
integrated ultrasound AI diagnosis product
•
Bioinformatics system platform
product approved and launched
•
CityU-MedAITech Joint Lab
established
•
Became a strategic partner of
the "Thousand-County Project", covering
over 200 hospitals
•
Recognized as a winning
organization in the “AI Medical Device
Innovation Task Leaderboard Program” organized by the Ministry of
Industry and Information Technology and the National Medical Products
Administration.
•
Recognized as a Potential
Unicorn Enterprise and a "Specialized,
Sophisticated, Distinctive, and Novel" Enterprise in Jiangsu Province
•
成功入选工信部人工智能医疗器械创新任务揭榜挂帅入围-优胜单位；
获得江苏省人工智能科学技术奖；江苏省优秀人工智能产品
•
入选 “滨湖之光”、“太湖人才”、省双创 等国家及省市级人才计划
•
获得了多张浅表脏器超声领域的二类医疗器械注册证；甲状腺超声三类证进入尾声
•
完成C轮融资
•
扩大科研与商业覆盖，达成数十项临床多中心重点合作以及省市级重点项目；
•
拓展商业覆盖，覆盖200多家医院
•
Selected by the Ministry of
Industry and Information Technology as a
lead unit for the AI medical-device innovation challenge
•
Awarded the Jiangsu Provincial
Artificial Intelligence Science and
Technology Award
•
Obtained multiple Class II
medical device registration certificates in
the field of superficial organ ultrasound; nearing completion of the
Class III certification for thyroid ultrasound
•
Completed Series C financing
•
Secured dozens of key clinical
multi-center collaborations as well as
provincial and municipal-level key projects
•
Expanded commercial coverage
to over 200 hospitals
•
省市两级准独角兽, 入选“滨湖之光”、“太湖人才”等计划
•
完成A及B轮融资
•
ITS 获得二类证，三类证， 临床试验多中心启动
•
成功亮相全国会议，开始商业化运营，在TOP100医院布局
•
Series A Financing
•
Series B Financing
•
Recognized as a National
High-Tech Enterprise and a Potential Unicorn
Enterprise in Wuxi
•
Launched the IBS series of AI
products for breast ultrasound
•
Launched and carried out
genomics-bioinformatics business
•
Selected for national,
provincial and municipal talent programs national
and provincial/municipal talent programs such as “Light of Binhu”,
“Taihu Talent”, the Provincial Dual-Innovation Program, and the Qiming
Talent Program.
•
Obtained NMPA registration and
launched commercial operations; completed
the layout in China's TOP 100 hospitals
•
完成 高企、瞪羚 资质入库
•
ITS100在知名合作医院试用落地
•
启动NMPA注册证二类、三类证申报
•
陆续达成与上市公司的重要渠道战略合作
•
拓展基于超声AI多种疾病产品研发
•
Completed the recognition of
"High and new technology enterprises to
cultivate storage"
•
Recognized as a Gazelle
Enterprise in Wuxi
•
Launched the ITS series of AI
products for thyroid ultrasound and
initiated NMPA registration
•
Western Data Center
established; initiated the high-quality gold
standard data construction project
•
Expanded research and
development of ultrasound AI products for multiple
diseases
•
完成天使轮融资
•
核心创始团队回国落地
•
落户无锡
•
成都研发中心落地
•
全国多家医院联合，多病种方向进行科研合作
•
选定超声人工智能作为公司战略方向
•
完成ITS100多中心方案设计
•
ITS系列产品1.0版本研发成功
•
Completed angel round
financing
•
Core founding team returned to
China and established operations
•
ettled in Wuxi
•
Chengdu R&D center established
•
Conducted scientific research
collaborations with multiple hospitals
nationwide across various disease areas
•
Selected ultrasound artificial
intelligence as the company's strategic
direction
•
Completed the multi-center
protocol design for ITS100
•
ITS series products version
1.0 successfully developed
脉得企业文化
Corporate
Culture of MED
Culture of MED
脉得愿景
Vision of MED
{{getlocset2('name4')}}
脉得使命
Mission of MED
为了人类的福祉
脉得核心价值观
Core Values of MED
{{getlocset2('name8')}}
脉得企业文化之中心
The Core of Corporate Culture
{{getlocset2('name10')}}
.png)